It is the no-DAC version, also called Modified GRF 1-29, with four enzyme-resistant amino acid substitutions that slow DPP-IV degradation and give it a half-life of about 30 minutes
In the obese trial cohort, 1 mg moved 24-hour heart rate by +0.7 bpm in the first week, essentially placebo. In a healthy lean Phase 1b group, the same dose raised heart rate by about 10 bpm, with a peak near 15 to 20 bpm around days 4 to 6. Lean, younger participants had more reactive heart-rate control than the sedentary, obese, and metabolically stressed trial population
Significant weight regain after obesity surgery that could benefit from additional medication support
Each body is unique, and outcomes are based on lifestyle, health requirements, and continued medical care
Kumar P
These clients are especially out of Scandinavian regions